Cited 9 times in
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2018-07-20T11:58:36Z | - |
dc.date.available | 2018-07-20T11:58:36Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/161572 | - |
dc.description.abstract | BACKGROUND: Dacomitinib is a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Pre-clinical data suggest that intermittent pulsatile dosing of dacomitinib may result in inhibition of EGFR T790M. METHODS: We evaluated safety, pharmacokinetics and efficacy of intermittent pulsatile dacomitinib in both molecularly unselected patients and patients with lung cancers harboring EGFR T790M (Clinical Trial Registration Number NCT01858389). RESULTS: Thirty-eight patients were treated on study with pulse dacomitinib; sixteen with EGFR T790M in Cohort A and 22 who were not molecularly selected in Cohort B. One patient out of 16 patients in Cohort A had a partial response to study therapy (ORR 6.3%, 95% CI 0.2-30.2%). The median progression-free survival (PFS) in Cohort A was 2.3 months and median PFS in Cohort B was 1.6 months. The adverse event profile was similar to standard daily dose dacomitinib with the most frequent treatment-related toxicities occurring in >20% of patients being diarrhea, rash, stomatitis, nausea, dry skin, paronychia, fatigue, and decreased appetite. CONCLUSION: Intermittent pulsatile dacomitinib is safe and relatively well tolerated but is not effective in patients that harbor EGFR T790M or in unselected patients with non-small cell lung cancer. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Scientific Publishers | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Helena A. Yu | - |
dc.contributor.googleauthor | Myung-Ju Ahn | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | David E. Gerber | - |
dc.contributor.googleauthor | Ronald B Natale | - |
dc.contributor.googleauthor | Mark A. Socinski | - |
dc.contributor.googleauthor | Nagdeep Giri | - |
dc.contributor.googleauthor | Susan Quinn | - |
dc.contributor.googleauthor | Eric Sbar | - |
dc.contributor.googleauthor | Hui Zhang | - |
dc.contributor.googleauthor | Giuseppe Giaccone | - |
dc.identifier.doi | 10.1016/j.lungcan.2017.08.017 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J02174 | - |
dc.identifier.eissn | 1872-8332 | - |
dc.identifier.pmid | 29191595 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0169500217304907 | - |
dc.subject.keyword | Dacomitinib | - |
dc.subject.keyword | Egfr | - |
dc.subject.keyword | Non-small-cell lung cancer | - |
dc.subject.keyword | Pulsatile dosing | - |
dc.subject.keyword | T790M | - |
dc.subject.keyword | Tyrosine kinase inhibitors | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.citation.volume | 112 | - |
dc.citation.startPage | 195 | - |
dc.citation.endPage | 199 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, Vol.112 : 195-199, 2017 | - |
dc.identifier.rimsid | 61600 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.